In December 2016, the US Food and Drug Administration (FDA) and Office for Human Research Protections (OHRP) finalized their guidance on electronic Informed Consent (eIC) in an effort to improve the patient experience and overall protections for human subjects. Since the paper process alone does not support the complexities of the concepts included in consents – from human rights to scientific procedures and study design – change was necessary. If followed correctly, the new final guidance will improve development and management of informed consents with effective presentation of information, compliance with informed consent regulations for multiple stakeholders, oversight by the investigator, plus many more areas.
Join us for this session which will outline how the new guidance and electronic systems can decrease – or even eliminate – the likelihood of quality gaps seen in the paper approach. Register for this presentation and you will:
This session is geared toward personnel from sites, sponsors/CROs, and ethics committees. It will also be of keen interest to anyone involved in the consent process, from trial personnel to legal staff.
Sandra “SAM” Sather is an industry-leading consultant whose mission is to promote clinical quality systems for Sponsors/CROs and Investigators/Research Institutions. She has over 25 years of clinical experience, with a Bachelor of Science in Nursing and a Master of Science in Education with a Specialization in Training and Performance Improvement. SAM is the vice-president of Clinical Pathways, a consulting firm located in the Research Triangle Park area in North Carolina, USA. SAM is dual certified by the Association for Clinical Research Professionals (ACRP) for over 10 years (CCRA and CCRC) and a current member of the ACRP Academy Board of Trustees and Regulatory Affairs Committee (RAC). She is a frequent speaker for industry conferences and has authored dozens of courses for clinical research in various functional areas (e.g., monitoring, safety, HIPAA, and vendor management).